secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269518
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Q3 2025 net loss narrows to $24.3M; cash at $989M; trial enrollment continues
--------------------------------------------------------------------------------

- Net loss of $24.3M improved from $28.1M in Q3 2024; R&D expense rose to $34.6M from $18.6M.
- Cash, equivalents & short-term investments totaled $989.0M, down from $1.03B at Dec 31, 2024.
- Enrollment ongoing in Phase 1 trials for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected Q4 2025.
- G&A expense fell to $10.6M vs $17.7M, last year included $9.5M stock-comp modification charge.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312525269518/0001193125-25-269518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312525269518/janx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer